This post is for paying subscribers only
Already have an account? Sign in.
Celcuity's Gedatolisib Shows Unprecedented Breast Cancer Trial Results
Phase 3 VIKTORIA-1 trial shows gedatolisib triplet slashed disease progression risk by 76% in HR+/HER2- advanced breast cancer, with favorable safety.